Surgery Partners, Inc. (SGRY)
Juste valeurFondamental
53
Prix
$13.87
Capitalisation boursière
$1.82B
Partie 1 · Ce que vaut l'entreprise
Vue d'ensemble
Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Bilan & Liquidités
Chiffre d'affaires
$3.37B
12 derniers mois (au 30/06/2026)
Résultat net
$-89M
12 derniers mois (au 30/06/2026)
Flux de trésorerie libre
$196M
Capitaux propres totaux
$1.71B
Passif total
$4.99B
Ratio de liquidité général
1.95
Couverture des intérêts
-
Dette/EBITDA
7.18
Bénéfice par action
Chiffre d'affaires & Résultat net
Flux de trésorerie libre
Décomposition du résultat
État historique
Marges dans le temps
La dette dans le temps
Le poids de la dette
Grille de la croissance
Croissance — Chiffre d'affaires
Estimation de la juste valeur
Juste valeur
$17.03
Prix actuel
$13.87
Marge de sécurité
+18.6%
Fourchette de juste valeur
$14.57 - $19.50
Écart entre les méthodes de valorisation utilisées, pas un intervalle de confiance calibré statistiquement.
Méthodes d'estimation
Indicateurs de valorisation
Ratio P/E
-
ROE
-4.5%
Ratio P/B
1.09
P/FCF
9.68
Marge brute
-
ROIC
4.1%
Radar de rentabilité
Création de valeur (avantage concurrentiel)
ROIC
4.1%
WACC
4.9%
ROIC − WACC
-0.8 pp
Le ROIC est à peu près aligné sur le coût du capital — l'entreprise couvre à peine son coût du capital.
Critères d'analyse fondamentale
Réussi (12)
- P/FCF 9.68
- P/B Ratio 1.09
- Debt/Equity ratio
- Operating Margin 11.4%
- Positive Free Cash Flow
- Current Ratio
- Revenue Growth 5Y 12.2%
- Analyst Consensus 78% Buy
- Earnings Surprise avg 14.8%
- Share Dilution 1.0%
- Net Margin Trend -2.6% vs -5.6%
- Piotroski F-Score 5/9
Échoué (9)
- EPS shows upward trend
- Price CAGR -0.85%
- ROIC 4.1%
- CapEx intensity
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- DCF valuation (Fairly valued)
- ROE -5.3%
Indisponible (6)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Score F de Piotroski
Signaux mixtes : certains domaines nécessitent attention
Qualité des bénéfices
Qualité faible : examiner la comptabilité
Dilution du capital
Le nombre d'actions est stable
Participations institutionnelles
Gouvernance
Équipe dirigeante
| Nom | Titre | Âge |
|---|---|---|
| Mr. J. Eric Evans | CEO & Director | 48 |
| Mr. David T. Doherty CPA | Executive VP & CFO | 53 |
| Ms. Jennifer B. Baldock J.D. | Executive VP and Chief Administrative & Development Officer | 54 |
| Ms. Marissa A. Brittenham | Executive VP & Chief Strategy Officer | 40 |
| Mr. W. Trent Webb | Division President South | 45 |
| Mr. Justin R. Oppenheimer | Executive VP & COO | 40 |
| Mr. Jon Fredrickson | Senior VP & Chief Information Officer | - |
| Ms. Roxanne Womack | Senior VP & Chief Compliance Officer | - |
| Mr. Spencer Clark | General Counsel & Senior VP | - |
| Ms. Danielle Burkhalter | Executive VP & Chief Human Resources Officer | 40 |
Risque d'audit
9
Risque du conseil
6
Risque de rémunération
4
Risque droits des actionnaires
8
Partie 2 · Le prix et le moment d'entrer
Cette partie ne dit pas si l'entreprise vaut la peine : elle aide à choisir quand l'acheter, une fois que les fondamentaux vous ont convaincu. À l'intérieur : analyse technique, potentiel, baisses historiques, exposition gamma.
Documents
- Voir le document
Rapport annuel (10-K)
Un aperçu annuel de l'activité, des résultats financiers et des risques de l'entreprise.
Déposé le 2026-03-02
- Voir le document
Rapport trimestriel (10-Q)
Une mise à jour de la performance financière des trois derniers mois.
Déposé le 2026-08-10
- Voir le document
Rapport d'événement important (8-K)
Un avis concernant un événement important, comme un changement de direction ou une annonce majeure.
Déposé le 2026-09-17
via SEC EDGAR
Historique des résultats
via SEC EDGAR
Latest News
Recent headlines for SGRY, sourced from Markets Gazette.
- 3/3/2026NEGATIVESurgery Partners Stock Hits 52-Week Low - Here's Why
Markets Gazette reports a significant downturn for Surgery Partners, whose shares (SGRY) hit a new 52-week low in premarket trading. The decline was triggered by the release of financial results that fell short of analysts' expectations. Furthermore, the company provided a cautious outlook for 2026, fueling investor concerns regarding future growth and profitability. This development suggests downward pressure on the stock, with the market reacting negatively to both current performance and near-term prospects. Investors should closely monitor the evolution of the company's strategy and upcoming reports to assess any signs of recovery.
- 2/23/2026NEGATIVESurgery Partners Stock Down 39% as One Fund Slashes Stake by $19 Million
Shares of Surgery Partners, a healthcare firm operating a national network of surgical centers, plummeted by a staggering 39%. The sharp decline was triggered by news that a major investment fund slashed its stake in the company, selling off shares worth $19 million. Such a substantial divestment by an institutional investor is a significant red flag for the market, often interpreted as a loss of confidence in the company's future prospects or valuation. This large-scale sell-off has created immense downward pressure on the stock, reflecting widespread investor concern. Traders will now be closely watching for any follow-up from the company or further signs of institutional selling to gauge the underlying reasons for the fund's exit.
via Markets Gazette